Five deals and acquisitions completed by drugmakers since the beginning of June, as reported by Becker's Hospital Review:
- Novo Nordisk signed a deal to acquire Irish biotech Prothena's experimental anti-amyloid heart drug and broader amyloidosis program.
- Eli Lilly acquired Protomer Technologies, a biotech that engineers peptides and proteins.
- GlaxoSmithKline signed a deal with iTeos Therapeutics to co-develop and co-commercialize its experimental monoclonal antibody cancer treatment.
- Merck signed a deal with the U.S. government under which it will receive $1.2 billion for 1.7 million courses of its COVID-19 antiviral drug molnupiravir if it's FDA-authorized.
- Walgreens sold its wholesaling arm, Alliance Healthcare, to AmerisourceBergen for $6.5 billion.